Sulopenem is under clinical development by Iterum Therapeutics and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Sulopenem’s likelihood of approval (LoA) and phase transition for Complicated Intra-Abdominal Infections took place on 23 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Sulopenem Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Sulopenem overview

Sulopenem (CP-70429) is under development for the treatment of complicated urinary tract infections, pyelonephritis, complicated intra-abdominal infections, community-acquired bacterial pneumonia, pelvic inflammatory disease and bacterial infections like acute bacterial prostatitis, gonococcal urethritis and bacillus anthracis Infections. It is administered through intravenous route. The drug candidate is a new penem beta-lactam antibiotic. It acts by targeting penicillin binding protein (PBP).

Iterum Therapeutics overview

Iterum Therapeutics is a clinical-stage pharmaceutical company. It develops anti-infectives for multi-drug resistant (MDR) pathogens for treating serious and life-threatening diseases. The company mainly develops Sulopenem, an oral and IV targeted-spectrum penem antibiotic for the treatment of infections caused by multi-drug resistant, gram-negative bacteria in both the hospital and community environments. Iterum Therapeutics seeks to work in partnership with other pharmaceutical companies for product development and commercialization opportunities. The company has operations with research and development facility in the US. Iterum Therapeutics is headquartered in Dublin, Ireland.

Quick View Sulopenem LOA Data

Report Segments
  • Innovator
Drug Name
  • Sulopenem
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Genito Urinary System And Sex Hormones
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.